Chronimed Renews HIV Disease Management Contract With Blue Shield Of California
MINNEAPOLIS, May 6, 1999 -- Chronimed Inc. (Nasdaq: CHMD), announced today that its wholly-owned subsidiary, Clinical Partners, signed a contract extension to perform HIV disease management with Blue Shield of California; the contract extends the relationship between the two companies to a fourth consecutive year. The relationship was developed to provide the best treatment options for Blue Shield patients living with HIV.
Jonathon Freudman, M.D., associate corporate medical director of Blue Shield, said, "We are very pleased to extend our contract with Clinical Partners for yet another year. During the previous three years of our relationship, there have been significant changes in the treatment of HIV. Clinical Partners' ability to help our physicians navigate through rapidly changing treatment guidelines has made a tremendous impact on the medical care of HIV positive Blue Shield members."
Henry F. Blissenbach, Pharm.D., president and chief operating officer of Chronimed, said, "Clinical Partners believes the key to managing HIV effectively is to involve the patient in their care. The focus of our program revolves around educating the patient, improving access to care, and reinforcing the need for strict adherence to treatment plans. In addition, we work with the patient's doctor to optimize therapy for the individual. As the preeminent HIV disease management program in the country we are delighted to partner with a patient focused organization such as Blue Shield."
Chronimed Inc. is a healthcare company specializing in services, products, and case management for patients with chronic health conditions. Such conditions include diabetes, HIV/AIDS, organ transplantation, and complex diseases treated with self-injectable drugs. The Company develops, manufactures, markets, and distributes pharmaceuticals, medical diagnostic products, and patient education materials nationwide directly to individuals, patients of managed care organizations, and to institutions that serves these patients.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of managed care contracts; and the risks described from time to time in the Company's SEC reports.
March 13, 2000
Contacts:
Paul S. Dunn
Investor Relations
or
Maurice R. Taylor, II
Chairman and CEO
Chronimed Inc.
(612) 979-3600